Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.

Novo Nordisk, the maker of Ozempic, has received a broker downgrade due to potential threats to its duopoly status in diabetes and weight loss markets. This downgrade suggests that the company's market position may be weakening. The analyst's warning indicates a potential shift in the competitive landscape